滋肾通阳活血方联合西药治疗冠心病心绞痛临床研究

Clinical Observation of Zishen Tongyang Huoxue Formula Combined with Western Medicine in Treatment of Angina Pectoris Caused by Coronary Heart Disease

目的观察滋肾通阳活血方联合西药治疗冠心病心绞痛临床疗效。方法将90例患者随机分为对照组、中药组、联合组各30例。对照组予常规西药治疗,中药组予滋肾通阳活血方治疗,联合组予滋肾通阳活血方联合常规西药治疗。3组疗程均为4周。观察治疗前后3组患者临床症状、心绞痛发作情况、心电图及血清生物标记物变化情况。结果 3组均可明显改善中医临床症状,缩短心绞痛持续时间,减少硝酸甘油用量,联合组疗效优于其他2组(P<0.05),中药组与对照组比较差异无统计学意义(P>0.05)。对照组、中药组、联合组临床总有效率分别为83.33%(25/30)、83.33%(25/30)、96.67%(29/30),联合组疗效优于其他2组(P<0.05);心电图总有效率分别为70.00%(21/30)、76.67%(23/30)、76.67%(23/30),3组比较差异无统计学意义(P>0.05)。治疗后,3组血清高敏C反应蛋白、白细胞介素-6和血清同型半胱氨酸水平均较治疗前降低(P<0.05),联合组降低程度更明显(P<0.05),中药组与对照组比较差异无统计学意义(P>0.05)。3组患者治疗后血常规及肝、肾功能均无异常变化(P>0.05)。结论滋肾通阳活血方联合常规西药治疗冠心病心绞痛疗效显著,安全可靠。

Objective To observe the clinical efficacy of Zishen Tongyang Huoxue Formula combined with western medicine in treating angina pectoris caused by coronary heart disease （CHD）.Methods Ninety patients were randomly divided into control group, TCM group and combining group, each group of 30 cases. The control group was given western medicine standardized treatment;the TCM group was treated with Zishen Tongyang Huoxue Formula only;the combining group took Zishen Tongyang Huoxue Formula and western medicine standardized treatment. The treatment course for the three groups lasted for four weeks. The clinical presentations, angina pectoris, ECG and serum biomarkers of patients in the three groups were assessed and evaluated before and after treatment.Results The clinical symptoms of TCM were significantly improved;the duration of angina was shortened;the dosage of nitroglycerin reduced after the treatment （P〈0.05）. The effects in the combining group was more evident compared with the other two groups （P〈0.05）, but there was no statistical difference between the other two groups （P〉0.05）. The total TCM effective rates of three groups were 83.33% （25/30）, 83.33% （25/30） and 96.67% （29/30）, respectively, among which the combining group was more significant （P〈0.05）. The total ECG effective rates of three groups were 70.00% （21/30）, 76.67% （23/30） and 76.67% （23/30）, respectively. Hs-CRP, IL-6 and HCY in the three groups decreased after the treatment （P〈0.05）. The combining group was more significant than the other two groups （P〈0.05）, but there was no statistical difference between the other two groups （P〉0.05）. Blood routine test and hepatorenal function of the three groups were all in normal range before and after treatment （P〉0.05）.Conclusion Using Zishen Tongyang Huoxue Formula combined with western medicinein to treat angina pectoris is effective, safe, and reliable.